Cargando…

The outcome of proliferative lupus nephritis with pulse cyclophosphamide therapy

Proliferative lupus nephritis deserves aggressive therapy and cyclophosphamide plays a pivotal role. Thirty nine patients with proliferative lupus nephritis (Class III-7 patients and Class IV- 32 patients) with a median follow up of 38 months were considered for this observational study. All the pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Annavarajula, S. K., Murty, K. V. D., Prayaga, A., Das, U., Desai, M., Narain, C. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161432/ https://www.ncbi.nlm.nih.gov/pubmed/21886974 http://dx.doi.org/10.4103/0971-4065.83933

Ejemplares similares

Mycophenolate versus Cyclophosphamide for Lupus Nephritis
por: Sahay, M., et al.
Publicado: (2018)

Revisited Cyclophosphamide in the Treatment of Lupus Nephritis
por: Quan, Xiao-ying, et al.
Publicado: (2022)

Molecular characterization of proliferative lupus nephritis
por: Parikh, Samir V, et al.
Publicado: (2014)

A Randomized Controlled Trial Comparing Remission Induction with Modified Multitarget Therapy with Intravenous Cyclophosphamide in Proliferative Lupus Nephritis
por: Pal, Atanu, et al.
Publicado: (2023)

Treatment with Methotrexate and Intravenous Cyclophosphamide Pulse Therapy Regulates the P-gp(+)CD4(+) Cell-related Pathogenesis in a Representative Patient with Refractory Proliferative Lupus Nephritis
por: Tsujimura, Shizuyo, et al.
Publicado: (2019)

Systematic evaluation of different doses of cyclophosphamide induction therapy for lupus nephritis
por: Tian, Ming, et al.
Publicado: (2017)

Non-histologic factors discriminating proliferative lupus nephritis from membranous lupus nephritis
por: Kwon, Oh Chan, et al.
Publicado: (2020)

Efficacy of Intravenous Cyclophosphamide Pulse Therapy for P-Glycoprotein-expressing B Cell-associated Active True Renal Lupus Vasculitis in Lupus Nephritis
por: Kawabe, Akio, et al.
Publicado: (2017)

Long-term renal outcomes of patients with non-proliferative lupus nephritis
por: Kang, Eun-Song, et al.
Publicado: (2023)

Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis
por: Olson, S. W., et al.
Publicado: (2017)

The history of pulse therapy in lupus nephritis (1976–2016)
por: Scheinberg, Morton
Publicado: (2016)

Rescue treatment of severe lupus myocarditis and proliferative lupus nephritis with immunoadsorption
por: Štambuk, Sandra Karanović, et al.
Publicado: (2023)

Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis
por: Romick-Rosendale, Lindsey E, et al.
Publicado: (2011)

Treatment Outcomes of Proliferative vs. Non-proliferative Adult Lupus Nephritis: A 10-Year Follow-Up
por: Zahab, Mohamed, et al.
Publicado: (2021)

Fish oil enhanced the efficacy of low-dose cyclophosphamide regimen for proliferative lupus nephritis: a randomized controlled double-blind trial
por: Zhang, Chi, et al.
Publicado: (2021)

Clinical features, epidemiology, and short-term outcomes of proliferative lupus nephritis in Eastern India
por: Sircar, D., et al.
Publicado: (2013)

Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis
por: Vachvanichsanong, Prayong, et al.
Publicado: (2012)

Mycophenolate or Cyclophosphamide in Lupus Nephritis: Which One to Use in Indian Patients?
por: Rathi, Manish, et al.
Publicado: (2018)

A Predictive Model for Estimation Risk of Proliferative Lupus Nephritis
por: Chen, Dong-Ni, et al.
Publicado: (2018)

Sickle cell nephropathy with diffuse proliferative lupus nephritis: a case report
por: Kanodia, Kamal V, et al.
Publicado: (2008)

Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide
por: Audemard-Verger, Alexandra, et al.
Publicado: (2016)

Cyclophosphamide Attenuates Fibrosis in Lupus Nephritis by Regulating Mesangial Cell Cycle Progression
por: Ma, Yuehong, et al.
Publicado: (2021)

Developing consensus treatment plans for proliferative lupus nephritis in childhood-onset systemic lupus erythematous
por: Mina, Rina, et al.
Publicado: (2012)

Clinicopathologic correlations of renal microthrombosis and inflammatory markers in proliferative lupus nephritis
por: Gonzalo, Elena, et al.
Publicado: (2012)

Differing environmental risk factors for membranous versus proliferative lupus nephritis
por: Dooley, MA, et al.
Publicado: (2012)

The Steroids In the Maintenance of remission of Proliferative Lupus nephritis (SIMPL) pilot trial
por: Galbraith, Lauren, et al.
Publicado: (2014)

Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial
por: Gheet, Fatma Sayed, et al.
Publicado: (2023)

Outcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center study
por: Sigdel, Mahesh R., et al.
Publicado: (2016)

Comparing the Efficacy and Safety of Induction Therapies for the Treatment of Patients with Proliferative Lupus Nephritis in South Africa
por: Sogayise, Phelisa, et al.
Publicado: (2020)

ANCA-Associated Necrotizing Glomerulonephritis Overlapping with Mesangial Proliferative Lupus Nephritis Refractory to Plasmapheresis, Steroid Pulse Therapy, and a Combination of Mycophenolate Mofetil and Rituximab
por: Sharmeen, Saika, et al.
Publicado: (2018)

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
por: Atisha‐Fregoso, Yemil, et al.
Publicado: (2020)

Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis
por: Häyry, Aliisa, et al.
Publicado: (2022)

Renal Tissue Expression of BAFF and BAFF Receptors Is Associated with Proliferative Lupus Nephritis
por: Marín-Rosales, Miguel, et al.
Publicado: (2022)

Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial
por: Sedhain, Arun, et al.
Publicado: (2018)

Methylprednisolone pulse therapy and intravenous cyclophosphamide therapy combined with cocktail therapy in severe pediatric Henoch-Schönlein purpura nephritis patient
por: Kanai, Hiroaki, et al.
Publicado: (2013)

Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study
por: Laskari, Katerina, et al.
Publicado: (2010)

Comparison of Two Steroid Regimens in Induction Therapy of Proliferative Lupus Nephritis: A Randomized Controlled Trial
por: Bharati, Joyita, et al.
Publicado: (2019)

Autoantigen microarrays reveal autoantibodies associated with proliferative nephritis and active disease in pediatric systemic lupus erythematosus
por: Haddon, D. James, et al.
Publicado: (2015)

Induction therapy and outcome of proliferative lupus nephritis in the top end of Northern Australia – a single centre study retrospective study
por: Xu, Chi, et al.
Publicado: (2022)

Individualizing Therapy in Lupus Nephritis
por: An, Yu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rk23brvpm1prnalp1epb9ol3qp